The use of MIPs in cancer medicine has been brought a step closer by the successful inhibition of the HER2 receptor on a particularly aggressive form of metastasising breast cancer cells. The nanoMIPs, targeting the glycans on the receptor protein, bind to HER2, and prevent the binding of growth factor, inhibiting the cells from proliferating. The effect has been demonstrated in vitro and in vivo (mice), showing inhibition in tumour growth. The report, from Zhen Liu and colleagues at Nanjing University, China is published in Angewandte Chemie International Edition and features in a press release as a hot paper from the journal.